Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B
Top Cited Papers
Open Access
- 1 January 2016
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 150 (1), 134-144.e10
- https://doi.org/10.1053/j.gastro.2015.09.043
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- HBsAg quantification: useful for monitoring natural history and treatment outcomeLiver International, 2013
- HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durabilityGut, 2013
- EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infectionJournal of Hepatology, 2012
- Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 updateHepatology International, 2012
- Chronic hepatitis B: Update 2009Hepatology, 2009
- High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long-term follow-up studyJournal of Hepatology, 2009
- Benefits and risks of interferon therapy for hepatitis BHepatology, 2009
- Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patientsHepatology, 2008
- Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factorsJournal of Hepatology, 2008
- Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment ResponseClinical Gastroenterology and Hepatology, 2007